Long-term Survival With Afatinib in a Patient With Lung Adenocarcinoma Harboring Double Uncommon EGFR L861Q and G719X Mutations

Background: In the majority of non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations, first generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are ineffective. The second-generation TKI, afatinib, is considered effective in patients with uncommon mu...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:In Vivo
Autores principales: OHARA, GEN, OKAUCHI, SHINICHIRO, SASATANI, YUIKA, SHIOZAWA, TOSHIHIRO, YAMADA, HIDEYASU, MIYAZAKI, KUNIHIKO, SATOH, HIROAKI
Formato: Artigo
Lenguaje:Inglês
Publicado: International Institute of Anticancer Research 2020
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7279823/
https://ncbi.nlm.nih.gov/pubmed/32354946
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/invivo.11929
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares